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Intrauterine Devices in the Context of  
Gonococcal Infection, Chlamydial Infection, and Pelvic Inflammatory Disease: 




The use of long-acting reversible contraception (LARC), namely intrauterine device (IUDs) and 
the subdermal implant, has been recommended to address the high rate of the unintended 
pregnancy in the United States.  IUDs are a safe, highly effective contraceptive method, suitable 
for most women.  The underutilization of IUDs arises in part from the lack of translation of best 
practices in the clinical setting as well as fears and misperceptions about this contraceptive 
method held by health care providers and women.  This article reviews screening and 
management of Neisseria gonorrhoeae and Chlamydia trachomatis infection and pelvic 
inflammatory disease in women who are using or want to use an IUD. An IUD may be inserted 
without prior screening for N gonorrhoeae or C trachomatis in low-risk, asymptomatic women.  
An in situ IUD may remain in the uterus during and after treatment for N gonorrhoeae, C 
trachomatis, or pelvic inflammatory disease (PID).  The risk of PID with an IUD in situ is less 
than 1%. Following IUD best practices, including their use in the context of sexually transmitted 
infections, can increase the availability of this method for suitable candidates and decrease the 
unintended pregnancy rate. 
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K.V. is 22-year-old woman who presents for her annual gynecological examination with 
her certified nurse-midwife (CNM). She had an induced abortion at a nearby clinic 3 months ago 
with no complications.  She was prescribed oral contraceptive pills (OCPs) at the clinic but 
missed “a bunch” so stopped taking them. She is currently not using any form of contraception 
and would like to resume OCPs.  K.V. had an appendectomy at age 12.  She has no other 
obstetric history or health conditions.  She is heterosexual and intermittently sexually active with 
the same partner for over two years.  She reports no history of sexually transmitted infections 
(STIs) or pelvic inflammatory disease (PID).  
Findings from the physical examination are normal, and a urine pregnancy test is 
negative. Neisseria gonorrhoeae and Chlamydia trachomatis tests were negative at her last visit 
one year ago and repeated at this visit. K.V. has no known contraindications to any 
contraceptive methods. Contraceptive options are discussed at length, including risks and 
benefits, and K.V. decides she would like an intrauterine device (IUD).  She is scheduled to 
return to the office for the IUD insertion in 2 weeks, which should coincide with her menses. 
K.V.’s C trachomatis test is positive. Azithromycin (Zithromax) is prescribed, and her IUD 
insertion visit that was scheduled for 2 weeks later is canceled.  No follow-up appointment is 
made, and K.V. has no reliable contraception. When the CNM learns of the situation 2 days 
later, she calls K.V. and explains that she can still have the IUD placed and that her infection 
will be cured before the date of the insertion.1,2  K.V. is hesitant to reschedule her IUD 
placement because she is worried about the risk of PID.  The CNM advises K.V. that the risk of 
PID with an IUD is less than 1%1,3 and reassures her of the efficacy and safety of the IUD. With 
K.V.’s continued uncertainty, the CNM offers her an appointment to revisit her contraceptive 
options and a prescription for an OCP for the interim. She encourages K.V. to use condoms to 
protect herself against pregnancy and STI.4,1 K.V. declines an office visit and OCP prescription 
stating she will consider all her options and call back.  K.V. never calls the office and does not 
respond to messages left by the CNM.   






In the United States, the unintended pregnancy rate is the highest for women between the 
ages of 20 and 25 years, at 81%.5  The Healthy People 2020 initiatives to decrease unintended 
pregnancy and increase the use of long-acting reversible contraception (LARC), including the 
intrauterine device (IUD) and implant, call upon women’s health care providers to offer effective 
contraception to appropriate candidates.6  The rate of unintended pregnancy may be reduced by 
women’s health care provider IUD counseling and provision.7  In the context of the STIs N 
gonorrhoeae and C trachomatis, some health care providers may not to adhere to IUD best 
practices.8  This article reviews evidence-based care for women with, or seeking, an IUD while 
experiencing a N gonorrhoeae or C trachomatis infection or PID.   
 
Intrauterine Devices 
LARC methods are 20 times more effective than other forms of contraception, such as 
OCPs.9  IUD insertion is an in-office procedure with few contraindications.9 There are currently 
5 IUDs available, 4 levonorgestrel-releasing IUDs varying in size and dose and one hormone-
free, copper IUD.9 These IUDs are effective for between 3 and 10 years, depending on the type.9  
Although LARC methods have a failure rate of less than 1%, they are underutilized, 
particularly in US women aged younger than 25 years.10,11  Overall use of IUDs among US 
women is 11.8%.12  The underutilization of IUDs stems, in part, from misinformation and fears 
about this method held by both health care providers and women.5,13  Some health care providers 
limit the use of IUDs due to a perceived risk of STIs, PID, and the possibility of subsequent 
ectopic pregnancy and infertility.14  While some health care providers and women remember an 
older generation of IUDs, such as the Dalkon Shield in the 1970s, that were linked with these 
complications, research on the currently available IUDs has found that they are safe, even with 
the diagnosis of a concomitant STI.1,15,16   
Women report the lack of information and access to appropriate contraceptive methods, 
especially the IUD, as barriers to the use of highly reliable contraception.13,17  Reluctance to use 
an IUD has been linked to “horror stories” communicated via friends and the media, fear of pain 
with insertion, fear of impairing future fertility, and historical injustices concerning the 
sterilization of Native American and black women.13,17  Some US women perceive a lack of 
contraceptive autonomy, particularly when they sense contraceptive coercion by their 
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provider.11,17  There may also be a perception of provider biases against socially marginalized 
women.17  Women of varying races report a sense of distrust in their provider, specifically when 
their provider is reluctant to remove LARC when requested.17  Through shared decision making, 
women’s health care providers can dispel misconceptions and offer unbiased, noncoercive, 
evidence-based information to facilitate a suitable contraceptive choice.13,17   
 
Candidates for Intrauterine Device Use 
IUDs are an appropriate contraceptive method for most women, regardless of their age, 
parity, and history of STIs and ectopic pregnancy.6,15  The US Medical Eligibility Criteria for 
Contraceptive Use (US MEC) is an evidence-based resource that summarizes recommendations 
for the safe use of contraceptive methods in the presence of medical conditions, such as migraine 
headache or diabetes, and other health characteristics, such as breastfeeding or medication use.15  
The US MEC classifies the use of each method of contraception on a scale of 1 to 4; a method 
categorized as a 1 may be used without reservation, a Category 4 indicates use of the 
contraception poses an unacceptable risk (see Table 1).15  IUD use is further categorized in terms 
of its initiation and continuation. Broadly speaking, IUD initiation and continuation is deemed 
acceptable (Category 1, 2, or 3) in most situations.15 IUD initiation is an unacceptable risk 
(Category 4) in the presence of a known or suspected active cervical or uterine infection, certain 
malignancies, and uterine anomalies.15   
A consideration of IUD use in adolescents and women aged younger than 25 years is the 
risk of STIs and potential for PID.  This age group has the highest risk of acquiring N 
gonorrhoeae and C trachomatis.1  IUDs do not protect against STIs; condoms are recommended 
for concomitant use.1,3   N gonorrhoeae and C trachomatis are among the leading causal agents 
for PID; however, having a history of either of these STIs is not a contraindication for IUD 
initiation or continuation.1,15  Likewise, women with a history of ectopic pregnancy or PID 
treated more than 3 months ago may be candidates for an IUD.1,15   In the presence of a known or 
suspected N gonorrhoeae or C trachomatis infection or PID, IUD insertion is delayed until 
screening is performed and/or treatment is completed.1,15  In the absence of a known cervical or 
uterine infection or purulent cervical discharge, an IUD may be inserted with an unknown N 
gonorrhoeae and C trachomatis status.1,15  
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Screening and Treatment for N gonorrhoeae or C trachomatis with Intrauterine Device Use 
N gonorrhoeae and C trachomatis may present asymptomatically, or mucopurulent 
cervical discharge, intermenstrual bleeding, or a friable cervix may be detected.1 N gonorrhoeae 
and C trachomatis may be detected through a nucleic acid amplification test (NAAT) of an 
endocervical or vaginal swab specimen or a first-void urine specimen at the time of IUD 
insertion.1  C trachomatis is treated with a one-time 1 g oral dose of azithromycin.1 N 
gonorrhoeae is treated with a one-time dose of ceftriaxone (Rocephin) 250 mg intramuscularly 
and azithromycin 1 g orally, due to the incidence of concomitant C trachomatis infection.1  
There are acceptable alternatives to these regimens (see Table 2).1  N gonorrhoeae and C 
trachomatis are considered cured one week after treatment.1  Therefore, the insertion of an IUD 
may proceed one week after the diagnosis and treatment of these infections.  If an IUD is in situ, 
it may remain in place during the treatment of N gonorrhoeae and C trachomatis.1  Rescreening 
for N gonorrhoeae and C trachomatis after treatment should take place in 3 months, unless 
reinfection is suspected sooner, but no sooner than 3 weeks after treatment to avoid a false-
positive from nonviable organisms still present in the vagina.1  
 
Treatment of Pelvic Inflammatory Disease in Women with an Intrauterine Device 
PID is caused by a myriad of bacteria in the genital tract, including N gonorrhoeae and C 
trachomatis.1 The presentation of PID can be vague but often includes pelvic or low abdominal 
pain.1  A low threshold for diagnosis and treatment should be practiced to avoid the potential 
sequelae of PID, including ectopic pregnancy and infertility.1 The minimum criteria for the 
diagnosis of PID is the presence of any one of the following: uterine tenderness, cervical motion 
tenderness, or adnexal tenderness.1 Other signs may include fever (temperature > 101oF), 
purulent cervical discharge, cervical friability, and elevated C-reactive protein or erythrocyte 
sedimentation rate values.1  Treatment regimens for uncomplicated, mild to moderately severe 
PID are presented in Table 3.1  Inpatient intravenous therapy is warranted in severe cases with 
high fever, nausea, vomiting, tubo-ovarian abscess, inability to tolerate oral treatment, or lack of 
response to oral or intramuscular antibiotics.1   
IUD insertion is contraindicated in women with current PID.1 If a woman who has an 
IUD develops PID, her IUD does not have to be removed.1  The removal of an IUD does not 
affect the course of active PID.15 IUD removal is indicated if PID is unresponsive to treatment or 
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the woman desires removal (see Figure 1).1,3 When IUD removal is needed, it should be delayed 
until 48 to 72 hours after the initiation of antibiotics to prevent dissemination of the infection.1,15   
 
Implications for Clinical Practice 
This case report highlights the use of IUDs in the context of STIs and PID and the need 
for women’s health care provider education and translation of best practices into clinical 
practice.18,19  Midwives have a role in the ongoing education of the interprofessional women’s 
health care team.  Consistency in women’s health care providers’ translation of IUD best 
practices into clinical practice needs improvement.8,20 It is important to ensure all health care 
providers, including those who provide primary and pediatric care, are aware the use of IUDs is 
recommended for young women and that STIs are not a contraindication for IUD use or 
continuation.1,15,21  
A woman’s lifelong contraceptive decision making is facilitated by her health care 
provider and her health care provider’s recommendations.22  Women’s health care providers can 
ensure access and provision of desired contraception at every visit. A recent study found that 
almost 25% of eligible women (n = 305) did not receive any form of contraception over the 
course of 450 cumulative visits to a health care setting.20 This study highlights the missed 
opportunity for contraception provision by women’s health care providers.20  
Ongoing women’s health care provider LARC training has increased health care provider 
IUD knowledge and utilization.18,19  A free, publicly available resource that can be used for 
health care provider training and dissemination of IUD best practices is the American College of 
Obstetricians and Gynecologists (ACOG) LARC Video Series.9  This set of videos covers 
various topics including IUD candidacy, counseling, informed consent, and clinical 
management.9 With women’s health care providers’ implementation of current IUD best 
practices, women may realize increased access to appropriate contraception, which can decrease 
the rate of unintended pregnancy.   
 
Conclusion 
In the United States, unintended pregnancy is a persistent public health problem.  Providing 
appropriate contraception can prevent unintended pregnancy.  While the evidence shows that 
most women are candidates and there are few contraindications to IUD use, some health care 
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providers may not offer IUDs to eligible candidates due to fears and lack of knowledge, 
particularly in the context of STIs and PID.9,22  The CDC and ACOG recommend health care 
providers offer IUDs as a safe contraceptive method, specifically to young women with the 
highest risk of unintended pregnancy.3.9  History of ectopic pregnancy or PID are not 
contraindications for IUD use; IUDs may be inserted in low-risk, asymptomatic women without 
prior N gonorrhoeae or C trachomatis screening.1,15 A diagnosis of N gonorrhoeae or C 
trachomatis infection or PID does not require removal of the IUD.1  Women’s health care 
providers serve women best by meeting their contraceptive needs.  Implementation of best 
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Table 1. US Medical Eligibility Criteria for Contraceptive Use Classification Categories  
1 A condition for which there is no restriction for the use of the contraceptive method. 
2 A condition for which the advantages of using the method generally outweigh the 
theoretical or proven risks. 
3 A condition for which the theoretical or proven risks usually outweigh the advantages of 
using the method. 
4 A condition that represents an unacceptable health risk if the contraceptive method is 
used. 





Table 2. Treatment of Uncomplicated N gonorrhoeae and C trachomatis Infections 





Recommended Regimens for C trachomatis 




Doxycycline (Doryx) 100 mg Oral 2 7 
 
Alternative Regimens for C trachomatis 
Erythromycin base (Ery-
Tab) 





succinate (EES 400) 








Ofloxacin (Floxin) 300 mg Oral 2 7 
 
Recommended Regimen for N gonorrhoeae 
Ceftriaxone (Rocephin) 250 mg IM 1 1 
plus 
Azithromycin (Zithromax)  1 g Oral 1 1 
 
Alternative Regimen for N gonorrhoeae: If ceftriaxone is not available 
Cefixime (Suprax) 400 mg Oral 1 1 
plus 
Azithromycin (Zithromax)  1 g Oral 1 1 
Source: Centers for Disease Control and Prevention.1 
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Table 3. Treatment of Mild to Moderately Severe Pelvic Inflammatory Disease 




Recommended Intramuscular/Oral Regimens 
Ceftriaxone (Rocephin) 250 mg IM 1 1 
plus 
Doxycycline (Doryx) 100 mg Oral 2 14 
with* or without 
Metronidazole (Flagyl) 500 mg Oral 2 14 
 
or 
Cefoxitin (Mefoxin) 2 g IM 1 1 
and 
Probenecid (Probalan) 1 g Oral 1 1 
plus 
Doxycycline (Doryx) 100 mg Oral 2 14 
with* or without 
Metronidazole (Flagyl) 500 mg Oral 2 14 
 
or 
Other parenteral third-generation cephalosporin (e.g., ceftizoxime or cefotaxime) 
plus 
Doxycycline (Doryx) 100 mg Oral 2 14 
with* or without 
Metronidazole (Flagyl) 500 mg Oral 2 14 
*The recommended third-generation cephalosporins are limited in the coverage of anaerobes. 
Therefore, until it is known that extended anaerobic coverage is not important for treatment of 
acute pelvic inflammatory disease, the addition of metronidazole to treatment regimens with 
third-generation cephalosporins should be considered. 














Figure 1.  Management of Pelvic Inflammatory Disease in Intrauterine Device Users 
*Treat according to CDC’s STD Treatment Guidelines (available at 
https://www.cdc.gov/std/treatment).  
Abbreviations: IUD, intrauterine device; PID, pelvic inflammatory disease.   
Source: Adapted from Center for Disease Control and Prevention.3 
 
 
